Ardelyx, Inc.
ARDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArdelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. Valued at $1.49B, ARDX is a small-cap name in its sector. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
Market Cap
$1.49B
Beta
0.61
P/E (TTM)
—
P/E (Fwd)
11.73
EPS (TTM)
$-0.24
EPS (Fwd)
$0.52
ROE
-39.5%
ROA
-5.1%
Cash
$238.1M
Total Debt
$234.1M
Free CF
$86,375
52W Change
56.9%
Annual Financials
Cash vs Debt
With $238.1M in cash and $234.1M in debt, ARDX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $86K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -39.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $52.2M (2022) to $407.3M (2025), reflecting a 681% increase over the period.
With a beta below 0.7, Ardelyx, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing ARDX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.